作者
Anja Lachenmayer, Clara Alsinet, Radoslav Savic, Laia Cabellos, Sara Toffanin, Yujin Hoshida, Augusto Villanueva, Beatriz Minguez, Philippa Newell, Hung-Wen Tsai, Jordi Barretina, Swan Thung, Stephen C Ward, Jordi Bruix, Vincenzo Mazzaferro, Myron Schwartz, Scott L Friedman, Josep M Llovet
发表日期
2012/9/15
期刊
Clinical cancer research
卷号
18
期号
18
页码范围
4997-5007
出版商
American Association for Cancer Research
简介
Purpose: Hepatocellular carcinoma (HCC) is a heterogeneous cancer with active Wnt signaling. Underlying biologic mechanisms remain unclear and no drug targeting this pathway has been approved to date. We aimed to characterize Wnt-pathway aberrations in HCC patients, and to investigate sorafenib as a potential Wnt modulator in experimental models of liver cancer.
Experimental Design: The Wnt-pathway was assessed using mRNA (642 HCCs and 21 liver cancer cell lines) and miRNA expression data (89 HCCs), immunohistochemistry (108 HCCs), and CTNNB1-mutation data (91 HCCs). Effects of sorafenib on Wnt signaling were evaluated in four liver cancer cell lines with active Wnt signaling and a tumor xenograft model.
Results: Evidence for Wnt activation was observed for 315 (49.1%) cases, and was further classified as CTNNB1 class (138 cases [21.5%]) or Wnt …
学术搜索中的文章
A Lachenmayer, C Alsinet, R Savic, L Cabellos… - Clinical cancer research, 2012
